Orphan diseases Market information, by Type of Diseases (autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders), Type of Treatment (gene therapy, cell therapy, drug therapy , End user (hospital and clinics, research laboratory) -Forecast to 2030
ID: MRFR/Pharma/1907-HCR | 85 Pages | Author: Kinjoll Dey | November 2023
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Value/Supply Chain Analysis
5.2 Porter's 5 Forces Analysis
5.3 Pricing Analysis
5.4 Investment Opportunity Analysis
5.5 Merger and Acquisition Landscape
6 Global Orphan diseases Market Market, By Disease Type (USD Million)
6.1 Introduction
6.2 Market Size By Disease Type
6.2.1 Autoimmune Disorders
6.2.2 Genetic Disorders
6.2.3 Blood Disorders
6.2.4 Cancer
6.2.5 Growth Disorder
6.2.6 Cardiovascular Diseases
6.2.7 Neurological Disorders
6.2.8 Respiratory Disorders
6.2.8 Digestive Disorders
6.2.9 Eye Disorders
6.2.10 Others
7 Global Chronic Disease Management Market, By Treatment Type (USD Million)
7.1 Introduction
7.2 Market Size By Treatment Type
7.2.1 Gene Therapy
7.2.2 Drug Therapy
7.2.3 Drug Therapy
7.2.4 Others
8 Global Chronic Disease Management Market, By End User (USD Million)
8.1 Introduction
8.2 Market Size By End User
8.2.1 Hospitals and Clinics
8.1.2 Research Laboratories
8.1.3 Others
9 Global Orphan Disease Market, By Region (USD Million)
9.1 Introduction
9.2 Market Size By Region
9.3 Market Size By Region
9.3.1 North America
9.3.1.1 The U.S.
9.3.1.2 Canada
9.3.2 Latin America
9.3.3 Europe
9.3.3.1 Western Europe
9.3.3.1.1 Germany
9.3.3.1.2 France
9.3.3.1.3 Italy
9.3.3.1.4 Spain
9.3.3.1.5 UK
9.3.3.2 Eastern Europe
9.3.4 Asia-Pacific
9.3.4.1 Asia
9.3.4.1.1 Japan
9.3.4.1.2 China
9.3.4.1.3 India
9.3.4.1.4 Australia
9.3.4.1.5 Republic of Korea
9.3.4.2 Rest of Asia-Pacific
9.3.5 Middle East & Africa
10 Company Landscape
10.1 Introduction: Key Players
10.2 Market Share Analysis
10.3 Key Development & Strategies
11 Company Profiles
11.1 Bristol-Myers Squibb Company
11.1.1 Company Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Novartis AG
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financials
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 CELGENE CORPORATION
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financials
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.4 F. Hoffmann-La Roche Ltd
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financials
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.5 Pfizer Inc.
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financials
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Alexion
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financials
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Sanofi
11.7.1 Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Vertex Pharmaceuticals Incorporated
11.8.1 Overview
11.8.2 Product/Business Segment Overview
11.8.3 Financials
118.4 Key Developments
11.8.5 SWOT Analysis
11.9 GlaxoSmithKline plc.
11.9.1 Overview
11.9.2 Product/Business Segment Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Merck & Co., Inc
11.10.1 Overview
11.10.2 Product/Business Segment Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 AbbVie Inc.
11.11.1 Overview
11.11.2 Product/Business Segment Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
List of Tables
TABLE 1 GLOBAL ORPHAN DISEASE MARKET, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL ORPHAN DISEASE MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TRATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE
FIGURE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER
FIGURE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION
FIGURE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Leading companies partner with us for data-driven Insights.
